02.10.16
Sanofi
4Q Revenues: €9.3 billion (+2%)
4Q Earnings: €1.7 billion (-7%)
FY Revenues: €37.1 billion (+10%)
FY Earnings: €7.4 billion (+8%)
Comments: Pharmaceutical sales were €7.3 billion in the quarter, down 5% at constant exchange rates (CER). Diabetes sales were €1.9 billion, down 13%, impacted by a decline Lantus sales (-20% to €1.5 billion) mainly reflecting higher discounts. Genzyme sales were €1.0 billion in the quarter, up 28% driven by Aubagio sales, up 70% to €272 million. Generics sales were €467 million, up 5%. Oncology sales were €381 million, down 8% impacted by lower sales of Eloxatin in the U.S (-24% to €58 million). Established Rx Products accounted for €2.7 billion, down 10% impacted by generic competition for Plavix (-14% to €455 million). Vaccines were up 15% to €1.4 billion, driven by influenza and Adult Booster vaccines and Meningitis/Pneumonia Vaccines in the U.S.
4Q Revenues: €9.3 billion (+2%)
4Q Earnings: €1.7 billion (-7%)
FY Revenues: €37.1 billion (+10%)
FY Earnings: €7.4 billion (+8%)
Comments: Pharmaceutical sales were €7.3 billion in the quarter, down 5% at constant exchange rates (CER). Diabetes sales were €1.9 billion, down 13%, impacted by a decline Lantus sales (-20% to €1.5 billion) mainly reflecting higher discounts. Genzyme sales were €1.0 billion in the quarter, up 28% driven by Aubagio sales, up 70% to €272 million. Generics sales were €467 million, up 5%. Oncology sales were €381 million, down 8% impacted by lower sales of Eloxatin in the U.S (-24% to €58 million). Established Rx Products accounted for €2.7 billion, down 10% impacted by generic competition for Plavix (-14% to €455 million). Vaccines were up 15% to €1.4 billion, driven by influenza and Adult Booster vaccines and Meningitis/Pneumonia Vaccines in the U.S.
